ALX Oncology Holdings Inc.
ALXONASDAQHealthcare● Active
$1.57
+$0.03(+1.95%)
Market Cap$211263780
P/E Ratio—
52W High$2.66
52W Low$0.404
ALX Oncology Holdings Inc. (ALXO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ALXO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.17
Est. -$0.15 · -13.3%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▼ Miss EPS
ALXO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.52
Rev. $3.34B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.52
Rev. Est.$3.34B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.15 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 8, 2026 | -$0.15 | -$0.17 | -13.3% | — | — | — |
| ▼ Q1 FY2026 | Feb 27, 2026 | -$0.38 | -$0.42 | -10.5% | — | — | — |
| ▼ Q4 FY2025 | Nov 7, 2025 | -$0.37 | -$0.41 | -10.8% | — | — | — |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.46 | -$0.49 | -6.5% | — | — | — |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.47 | -$0.58 | -23.4% | — | — | — |
| ▲ Q1 FY2025 | Mar 6, 2025 | -$0.72 | -$0.55 | +23.6% | — | — | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.78 | -$0.58 | +25.6% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.15
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Miss
EPS Actual
-$0.17
EPS Est.
-$0.15
EPS Surpr.
-13.3%
Revenue
—
Q1 FY2026
Feb 27, 2026Miss
EPS Actual
-$0.42
EPS Est.
-$0.38
EPS Surpr.
-10.5%
Revenue
—
Q4 FY2025
Nov 7, 2025Miss
EPS Actual
-$0.41
EPS Est.
-$0.37
EPS Surpr.
-10.8%
Revenue
—
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.49
EPS Est.
-$0.46
EPS Surpr.
-6.5%
Revenue
—
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.58
EPS Est.
-$0.47
EPS Surpr.
-23.4%
Revenue
—
Q1 FY2025
Mar 6, 2025Beat
EPS Actual
-$0.55
EPS Est.
-$0.72
EPS Surpr.
+23.6%
Revenue
—
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.58
EPS Est.
-$0.78
EPS Surpr.
+25.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q3 FY2027 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Q2 FY2027 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Q1 FY2027 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Q4 FY2026 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q3 FY2026 | $-0.16 | $-0.15 | $-0.14 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 8, 2026 | -13.3% | $1.87 | $2.08 | +11.23% |
| ▼ Q1 FY2026 | Feb 27, 2026 | -10.5% | $2.35 | $2.11 | -10.21% |
| ▼ Q4 FY2025 | Nov 7, 2025 | -10.8% | $1.18 | $1.38 | +16.95% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -6.5% | $0.61 | $0.62 | +0.10% |
| ▼ Q2 FY2025 | May 8, 2025 | -23.4% | $0.48 | $0.46 | -4.94% |
| ▲ Q1 FY2025 | Mar 6, 2025 | +23.6% | $1.04 | $1.31 | +25.96% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +25.6% | $1.53 | $1.51 | -1.31% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +1.3% | $2.57 | $2.63 | +2.33% |
Q2 FY2026+11.23%
Report Date
May 8, 2026
EPS Beat/Miss
-13.3%
Price Before
$1.87
Price After
$2.08
Q1 FY2026-10.21%
Report Date
Feb 27, 2026
EPS Beat/Miss
-10.5%
Price Before
$2.35
Price After
$2.11
Q4 FY2025+16.95%
Report Date
Nov 7, 2025
EPS Beat/Miss
-10.8%
Price Before
$1.18
Price After
$1.38
Q3 FY2025+0.10%
Report Date
Aug 12, 2025
EPS Beat/Miss
-6.5%
Price Before
$0.61
Price After
$0.62
Q2 FY2025-4.94%
Report Date
May 8, 2025
EPS Beat/Miss
-23.4%
Price Before
$0.48
Price After
$0.46
Q1 FY2025+25.96%
Report Date
Mar 6, 2025
EPS Beat/Miss
+23.6%
Price Before
$1.04
Price After
$1.31
Q4 FY2024-1.31%
Report Date
Nov 7, 2024
EPS Beat/Miss
+25.6%
Price Before
$1.53
Price After
$1.51
Q3 FY2024+2.33%
Report Date
Aug 8, 2024
EPS Beat/Miss
+1.3%
Price Before
$2.57
Price After
$2.63
Avg Beat Reaction+8.99%
Avg Miss Reaction+2.63%
Beat Rate3 / 8 quarters
Largest Move+25.96% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ALXO ends December
ALX Oncology Holdings Inc. (ALXO) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.17 — missing the analyst consensus of $-0.15 by -13.3%. The next ALXO earnings date is expected around September 1, 2026.
Each quarter, investors track ALXO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ALXO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ALXO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ALXO earnings · 5 questionsALX Oncology Holdings Inc.'s next earnings report is expected around September 1, 2026. ALXO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ALXO historically reports after market close (AMC).
ALXO earnings datewhen is ALXO earningsALXO next earnings datewhen does ALXO report earningsALXO earnings calendar
▸ Source: FMP · ALX Oncology Holdings Inc. SEC filings · US GAAP · ALX Oncology Holdings Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026